Floatz logo

Diphenhydramine

Refractory Hematologic Cancer

Explore 6 assets in Refractory Hematologic Cancer →
Floatz Rating
CC47/100
Confidence
Indicative
v0.2
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT04681105CT.gov
Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Refractory Hematologic Cancer

AssetSponsorPhaseRating
Diphenhydramine (this asset)City of Hope Medical CenterP1CC · 47
RivoceranibZhengzhou UniversityP4BB
Humanized, Dual-Affinity Re-Targeting, Or (Dart), Molecule That Recognizes Both Cd123 And Cd3City of Hope Medical CenterP2CCC
Gm-CsfThe First Affiliated Hospital of Xiamen UniversityP2CCC
LenalidomideThe First Affiliated Hospital of Xiamen UniversityP2CCC
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)The First Affiliated Hospital of Xiamen UniversityP2CCC
EmavusertibCuris, Inc.P1/2CCC
IbrutinibCuris, Inc.P1/2CCC
RanitidineCity of Hope Medical CenterP1CC

+42 more in the Refractory Hematologic Cancer cohort

Other indications for Diphenhydramine

IndicationSponsorPhaseRating
Plasma Cell Myeloma—P4BB · 66
Migraine Disorder—P4BB · 66
Non-Hodgkin Lymphoma—P2BB · 64

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Diphenhydramine in Refractory Hematologic Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 13, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/diphenhydramine-refractory-hematologic-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →